SHANGHAI -- China's Clover Biopharmaceuticals is set to debut on the Stock Exchange of Hong Kong on Friday as it races to win regulatory approval and begin shipments of its COVID-19 vaccine.
Though founded in 2007, Chengdu-based Clover has yet to generate any operating revenue. Development of its COVID vaccine was financed by a grant worth up to $360.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI), the disease research funding group set up by the Gates Foundation, Japan, the EU and other governments.
